This update serves to clarify that Amersham has not sold its CodeLink business to EMBL, but rather a CodeLink system for internal research.
NEW YORK, Jan. 21 (GenomeWeb News) - Amersham Biosciences has sold a CodeLink microarray platform to the European Molecular Biology Laboratory, Amersham said today.
EMBL's genomics core facility in Heidelberg will offer gene-expression services based on the technology to EMBL groups and their collaborators. In addition, EMBL and Amersham will jointly organize training and access to the platform. An EMBL developmental biology research groups has already been using CodeLink microarrays to study gene expression in mice, according to Amersham.
According to the EMBL website, its core facility is also offering services using Affymetrix's gene expression platform.